Lifespan Vision Ventures is leading a planned $10 million Series A financing for Remedium Bio, completing the round’s initial closing with participation from Eli Lilly and Company and HKX Capital as the biotechnology company advances its durable protein therapeutics platform toward human clinical development.
The investment will provide Remedium with capital to advance its lead programs, expand its underlying technology platform and prepare for first-in-human clinical studies. The companies did not disclose how much of the planned $10 million was included in the initial closing.
As part of the financing, Harry Robb of Lifespan Vision Ventures has joined Remedium’s board of directors, giving the venture firm a direct role as the company moves from preclinical development toward the clinic.
Remedium is developing an approach intended to provide controlled, long-lasting production of therapeutic proteins following minimally invasive subcutaneous administration. Its technology uses adipocytes, or fat cells, as a durable site for producing therapeutic proteins inside the body.
The company is seeking to achieve multi-year therapeutic benefits while retaining the ability to adjust expression levels after treatment. If successfully demonstrated in clinical studies, that combination could address limitations associated with chronic biologic therapies that require repeated injections and can produce variations in drug exposure over time.
“Remedium has built a differentiated platform with the potential to address important limitations of chronic biologic therapy,” said Andrew Worden, founding partner of Lifespan Vision Ventures. “We are proud to lead the Series A financing and support the company as it advances its pipeline toward clinical development and expands the potential of its platform.”
The investment fits Lifespan Vision Ventures’ focus on early-stage biotechnology companies developing technologies targeting age-related diseases and healthy aging. Remedium provides the firm with exposure to a platform that could potentially be applied across multiple chronic disease categories rather than a single therapeutic program.
Remedium’s proprietary Prometheus platform is designed to replace certain frequently administered protein therapies with single-injection, adjustable gene therapies. The company is developing programs across endocrinology, immunology, neurology and musculoskeletal diseases, with the current financing expected to support milestones in cardiometabolic and other chronic conditions.
The platform strategy gives Remedium several potential paths for growth if its underlying delivery technology translates successfully into human studies. Instead of developing a separate delivery approach for each therapeutic candidate, the company aims to use the same core technology across multiple proteins and disease areas.
That potential breadth is a key part of the investment thesis. Chronic diseases often require treatment over extended periods, creating a significant market for therapies capable of reducing dosing frequency while maintaining appropriate therapeutic exposure. Remedium’s approach is designed to combine durability with post-treatment dose adjustment, addressing a challenge associated with therapies that produce long-lasting biological effects.
The participation of Lilly also brings a major pharmaceutical company into the Series A investor group as Remedium prepares for clinical development. No strategic rights, licensing arrangements or other commercial terms associated with Lilly’s investment were disclosed.
“Lifespan Vision Ventures shares our belief that durable therapies have the potential to fundamentally improve the treatment of chronic disease,” said Frank Luppino, CEO of Remedium Bio. He said the financing will support expansion of the company’s pipeline and preparations for first-in-human development.
The Series A follows progress across Remedium’s preclinical programs and strategic collaborations. The company expects the capital to help generate additional evidence demonstrating whether its platform can be applied across a broader range of chronic diseases.
For Lifespan Vision Ventures, leading the financing represents a bet on a technology platform approaching an important transition point. Remedium must now move from preclinical development toward human testing, where safety, durability and the ability to control therapeutic protein expression will become central measures of the platform’s potential.
Completion of the full $10 million Series A would give Remedium additional resources for that development program while strengthening its investor base with biotechnology-focused venture capital and pharmaceutical industry participation.
